LBSR TO DA MOON,
At this point traders coming in to position before news and some smaller nervous shorts seeing need to cover. Most shorts might be trying to anchor the price below $5 for as long as possible for others to enter in as cheap as possible. The price right now does not reflect anything close to normal true value for a platform product about to seek approval in the toughest to treat cancer indication that has advanced manufacturing in place and is being validated. The fact that this threat needed to be contained has been obvious for years now considering how much money is being made by checkpoint inhibitors and the threat to SOC in many types of cancer and beyond.
With the right news from submission and manufacturing, traders and longs could make it a fast dog fight at $5 by pushing it past there quickly to a more realistic spec value but that would take a very aware public with significant media attention while waiting for approval. If this media attention arrives value by investors will be based on the leveraged position of this platform with other treatments that need this as a base for future earnings growth and proof that impediments to commercial scale manufacturing have been remedied. The right kind of manufacturing news creates a no guess approval decision for a treatment that is listed as a national priority in the UK. This then launches a slew of analyst reports that can be created with valid numbers based on known capacity and any limiting factors such as reimbursement streams and inventory and availability of necessary components needed with each new jurisdiction added into the demand model. Much of this is likely to be worked out with CRL and perhaps others that analysts would be familiar with and trust with time lines for roll out and revenue predictions on their end. Best wishes.
News 
Market Data 
Discover 
AI
